[go: up one dir, main page]

CY1116873T1 - ACE2 polypeptide - Google Patents

ACE2 polypeptide

Info

Publication number
CY1116873T1
CY1116873T1 CY20151100955T CY151100955T CY1116873T1 CY 1116873 T1 CY1116873 T1 CY 1116873T1 CY 20151100955 T CY20151100955 T CY 20151100955T CY 151100955 T CY151100955 T CY 151100955T CY 1116873 T1 CY1116873 T1 CY 1116873T1
Authority
CY
Cyprus
Prior art keywords
ace2 polypeptide
dimer
ace2
polypeptide
life
Prior art date
Application number
CY20151100955T
Other languages
Greek (el)
Inventor
Manfred Schuster
Hans Loibner
Evelyne Janzek-Hawlat
Bernhard Peball
Stefan Stranner
Bettina Wagner
Robert Weik
Original Assignee
Apeiron Biologics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08450052A external-priority patent/EP2108695A1/en
Application filed by Apeiron Biologics Ag filed Critical Apeiron Biologics Ag
Publication of CY1116873T1 publication Critical patent/CY1116873T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ανασυνδυασμένο πολυπεπτίδιο ACE2, όπου το πολυπεπτίδιο ACE2 υφίσταται ως διμερές. Το διμερές σχηματίζεται ειδικότερα από γλυκοζυλιωμένα μονομερή και χρησιμοποιείται για την παρασκευή φαρμακευτικών προϊόντων με παρατεταμένο χρόνο ημιζωής.The present invention relates to a recombinant ACE2 polypeptide, wherein the ACE2 polypeptide exists as a dimer. The dimer is formed in particular from glycosylated monomers and is used for the preparation of medicinal products with prolonged half-life.

CY20151100955T 2007-06-12 2015-10-26 ACE2 polypeptide CY1116873T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0091307A AT505262A1 (en) 2007-06-12 2007-06-12 New recombinant angiotensin I converting enzyme 2 polypeptide comprising specific amount of glycosylated and sugar portion, useful for enzyme substitution therapy for treating acute respiratory distress syndrome or acute lung injury
EP08450052A EP2108695A1 (en) 2008-04-08 2008-04-08 Ace2 polypeptide
EP08756821.8A EP2155871B1 (en) 2007-06-12 2008-06-12 Ace2 polypeptide

Publications (1)

Publication Number Publication Date
CY1116873T1 true CY1116873T1 (en) 2017-04-05

Family

ID=39720296

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100955T CY1116873T1 (en) 2007-06-12 2015-10-26 ACE2 polypeptide
CY20181100549T CY1120426T1 (en) 2007-06-12 2018-05-23 ACE2 polypeptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20181100549T CY1120426T1 (en) 2007-06-12 2018-05-23 ACE2 polypeptide

Country Status (35)

Country Link
US (3) US8586319B2 (en)
EP (3) EP3375872A1 (en)
JP (1) JP5731193B2 (en)
KR (2) KR101682240B1 (en)
CN (2) CN104450654A (en)
AT (1) AT505262A1 (en)
AU (1) AU2008261591B2 (en)
BR (1) BRPI0813942B8 (en)
CA (1) CA2692854C (en)
CO (1) CO6270265A2 (en)
CR (1) CR11213A (en)
CY (2) CY1116873T1 (en)
DK (2) DK2543724T3 (en)
DO (1) DOP2009000282A (en)
EA (1) EA027399B1 (en)
EG (1) EG27095A (en)
ES (2) ES2670938T3 (en)
HK (1) HK1255493A1 (en)
HR (2) HRP20151120T1 (en)
HU (2) HUE028012T2 (en)
IL (1) IL202653B (en)
LT (1) LT2543724T (en)
MA (1) MA31472B1 (en)
MX (1) MX2009013472A (en)
MY (1) MY180672A (en)
NO (1) NO2543724T3 (en)
NZ (1) NZ581704A (en)
PL (2) PL2543724T3 (en)
PT (2) PT2155871E (en)
RS (2) RS57292B1 (en)
SI (2) SI2543724T1 (en)
TR (1) TR201808117T4 (en)
UA (1) UA106869C2 (en)
WO (1) WO2008151347A1 (en)
ZA (1) ZA200908751B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
AT505262A1 (en) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und New recombinant angiotensin I converting enzyme 2 polypeptide comprising specific amount of glycosylated and sugar portion, useful for enzyme substitution therapy for treating acute respiratory distress syndrome or acute lung injury
EP2077119A1 (en) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Treatment of fibrosis and liver diseases
AT506632A1 (en) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und TREATMENT OF TUMOR DISEASES
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2013157002A1 (en) 2012-04-19 2013-10-24 Prolor Biotech Inc. Long-acting oxyntomodulin variants and methods of producing same
RU2015106812A (en) 2012-08-02 2016-09-27 Ф.Хоффманн-Ля Рош Аг METHOD FOR PRODUCING MONOMERIC AND MULTIMETERAL MOLECULES AND THEIR APPLICATION
EA033788B1 (en) 2012-11-20 2019-11-26 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptide by attaching to gonadotrophin carboxy terminal peptide
KR20150110607A (en) * 2013-01-14 2015-10-02 아페이론 바이오로직스 아게 Modified ace2 polypeptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN107438623B (en) 2014-12-10 2023-07-14 Opko生物科学有限公司 Preparation method of long-acting CTP-modified growth hormone polypeptide
HUE055449T2 (en) 2015-06-19 2021-11-29 Opko Biologics Ltd Long-acting coagulation factors and methods for their production
TW202444744A (en) 2016-07-11 2024-11-16 以色列商歐科生物製品有限公司 Long-acting coagulation factors and methods of producing same
US11518788B2 (en) * 2020-07-10 2022-12-06 Avirus, Inc. Methods and compositions for treating and preventing viral infection
WO2021151043A2 (en) * 2020-01-23 2021-07-29 Jang Hyun Han Methods and compositions for treating and preventing viral infection
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
EP3884957A1 (en) 2020-03-26 2021-09-29 The University of British Columbia Methods for treatment of virus and methods for screening of anti-virus reagent using organoids
US20230293647A1 (en) * 2020-04-09 2023-09-21 Autolus Limited Polypeptide
WO2021217120A2 (en) * 2020-04-24 2021-10-28 Administrators Of The Tulane Educational Fund Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor
CN113667016A (en) * 2020-05-15 2021-11-19 普米斯生物技术(珠海)有限公司 Platform for constructing coronavirus antibody
WO2021247675A1 (en) 2020-06-02 2021-12-09 Ngm Biopharmaceuticals, Inc. Coronavirus-binding agents and uses thereof
DE102020207224A1 (en) 2020-06-09 2021-12-09 Christoph Karle Protein or peptide, in particular for the prophylaxis and / or treatment of an infection or infectious disease and / or a sequela thereof caused by coronaviruses, in particular SARS-CoV-2 viruses
EP4171603A4 (en) * 2020-06-25 2024-06-26 Gliknik Inc. ACE2-FC FUSION PROTEINS AND METHODS OF USE
WO2022008642A1 (en) 2020-07-08 2022-01-13 Apeiron Biologics Ag Treatment of sars-cov-2 infection with a combination of targets
KR20230066317A (en) * 2020-07-10 2023-05-15 바이오몰레큘러 홀딩스 엘엘씨 tetrahedral antibody
US20240035012A1 (en) * 2020-08-21 2024-02-01 Westlake University Engineered ace2 oligomers and uses thereof
KR102725210B1 (en) * 2020-10-05 2024-11-04 한양대학교 산학협력단 Stabilized Ace2 Mutant, Ace2-Fc Fusion Protein Using Same and Pharmaceutical Composition for Preventing or Treating COVID-19
CN112280764A (en) * 2020-11-18 2021-01-29 通用生物系统（安徽）有限公司 Production method of novel crown recombinant ACE2 protein in mammalian cells
EP4011387A1 (en) 2020-12-11 2022-06-15 IMBA-Institut für Molekulare Biotechnologie GmbH Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2
US20220226489A1 (en) 2021-01-20 2022-07-21 Singh Biotechnology, Llc Therapeutics directed against coronavirus
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022207918A1 (en) 2021-04-02 2022-10-06 Apeiron Biologics Ag COVID-19 Therapy
EP4387732A4 (en) 2021-08-19 2025-09-03 Phenom Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF SARS COV-2
KR102834587B1 (en) * 2021-09-16 2025-07-17 인에이블앱 주식회사 Angiotensin converting enzyme 2 and uses thereof
CN113897346A (en) * 2021-09-16 2022-01-07 四川大学 ACE2 mutant combination capable of improving affinity with SARS-CoV-2S protein and application thereof
DE102023118690A1 (en) 2023-07-14 2025-01-16 Christoph Karle Protein or peptide, in particular for the prophylaxis and/or treatment of an infection and/or infectious disease and/or a secondary disease thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
DE60324925D1 (en) 2002-06-19 2009-01-08 Univ Health Network ACE2 ACTIVATION FOR THE TREATMENT OF HEART, LUNG, AND CHILDNESS AND BLOOD HIGH PRESSURE
WO2004023270A2 (en) 2002-09-09 2004-03-18 Millenium Pharmaceuticals, Inc. Crystal structure of angiotensin-converting enzyme-related carboxypeptidase
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
AT504443B1 (en) 2006-10-19 2008-11-15 Apeiron Biolog Forschungs Und METHOD FOR DETERMINING THE ACTIVITY OF ACE2
AT505262A1 (en) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und New recombinant angiotensin I converting enzyme 2 polypeptide comprising specific amount of glycosylated and sugar portion, useful for enzyme substitution therapy for treating acute respiratory distress syndrome or acute lung injury
EP2108695A1 (en) 2008-04-08 2009-10-14 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Ace2 polypeptide
AT506258A1 (en) * 2007-12-18 2009-07-15 Apeiron Biolog Forschungs Und TREATMENT OF INFLAMMATORY DISEASES
AT506632A1 (en) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und TREATMENT OF TUMOR DISEASES

Also Published As

Publication number Publication date
TR201808117T4 (en) 2018-07-23
SI2155871T1 (en) 2015-11-30
HRP20180856T1 (en) 2018-08-24
US8586319B2 (en) 2013-11-19
EP2155871A1 (en) 2010-02-24
CR11213A (en) 2010-04-20
RS57292B1 (en) 2018-08-31
EP2543724A3 (en) 2013-02-20
CY1120426T1 (en) 2019-07-10
JP5731193B2 (en) 2015-06-10
HUE037877T2 (en) 2018-09-28
ZA200908751B (en) 2010-07-28
KR20160054045A (en) 2016-05-13
MA31472B1 (en) 2010-06-01
US20180289779A1 (en) 2018-10-11
WO2008151347A1 (en) 2008-12-18
EA027399B1 (en) 2017-07-31
BRPI0813942A2 (en) 2014-12-30
CN101796183A (en) 2010-08-04
HK1136602A1 (en) 2010-07-02
BRPI0813942B8 (en) 2021-05-25
CN104450654A (en) 2015-03-25
LT2543724T (en) 2018-06-25
PL2543724T3 (en) 2018-08-31
UA106869C2 (en) 2014-10-27
US10716833B2 (en) 2020-07-21
RS54340B1 (en) 2016-02-29
PT2543724T (en) 2018-06-11
JP2011519264A (en) 2011-07-07
CA2692854C (en) 2017-07-04
CA2692854A1 (en) 2008-12-18
AT505262A1 (en) 2008-12-15
MY180672A (en) 2020-12-05
EP2155871B1 (en) 2015-08-12
NZ581704A (en) 2012-05-25
DOP2009000282A (en) 2010-03-31
IL202653A0 (en) 2011-08-01
CO6270265A2 (en) 2011-04-20
ES2670938T3 (en) 2018-06-04
IL202653B (en) 2018-01-31
EP2543724B1 (en) 2018-03-21
BRPI0813942B1 (en) 2019-08-20
MX2009013472A (en) 2010-06-25
ES2550390T3 (en) 2015-11-06
SI2543724T1 (en) 2018-07-31
DK2543724T3 (en) 2018-05-28
US20100310546A1 (en) 2010-12-09
DK2155871T3 (en) 2015-11-09
EP2543724A2 (en) 2013-01-09
HRP20151120T1 (en) 2015-11-20
US20140099297A1 (en) 2014-04-10
HK1255493A1 (en) 2019-08-16
AU2008261591A1 (en) 2008-12-18
PL2155871T3 (en) 2015-12-31
KR20100040809A (en) 2010-04-21
EA201000002A1 (en) 2010-08-30
PT2155871E (en) 2015-10-26
AU2008261591B2 (en) 2014-08-07
HUE028012T2 (en) 2016-11-28
EP3375872A1 (en) 2018-09-19
KR101682240B1 (en) 2016-12-06
NO2543724T3 (en) 2018-08-18
EG27095A (en) 2015-05-28

Similar Documents

Publication Publication Date Title
CY1116873T1 (en) ACE2 polypeptide
CY1123419T1 (en) HIGH AFFINITY SIRP-ALPHA REAGENTS
CY1121419T1 (en) INHIBITION OF FUCOSYLING OF PROTEINS IN VIVO USING FUCOCZE PROPORTIONS
CY1115649T1 (en) LONG-ACTION INSULIN PREPARATIONS
CL2013003090A1 (en) Polypeptide comprising a first amino acid sequence which in turn comprises at least one individual variable immunoglobulin domain that specifically binds to il-17f, il17-a / f, but not to il-17a, and a second amino acid sequence that it comprises at least one individual variable domain of immunoglobulin that specifically binds to il-17a, il-17f and il17-a / f; pharmaceutical composition that includes it; And its use.
WO2012175222A8 (en) AN IL-15 AND IL-15Rα SUSHI DOMAIN BASED IMMUNOCYTOKINES
CY1117479T1 (en) BROMODOMAIN BENZODIAZEPINIC SUSPENSION
CY1116064T1 (en) DDP Suspension Recommendations IV
EP4269441A3 (en) Il-15 and il-15ralpha sushi domain based on modulokines
WO2010034718A8 (en) Recombinant proteins having haemostatic activity and capable of inducing platelet aggregation
CY1111833T1 (en) BILATERAL PRODUCTS OF ARTEMISININ, THEIR PREPARATION AND THEIR APPLICATION TO THERAPEUTICS
CA2818990A1 (en) Designed repeat proteins binding to serum albumin
EA200801460A1 (en) Recombinant Monovalent Antibodies and Methods for Their Production
BR102014018011A8 (en) composition, use and food product
WO2012016227A3 (en) Antibodies with modified isoelectric points
MY160552A (en) Low protein infant formula with increased essential amino acids
TR201900207T4 (en) Factor VIII Formulations
WO2014052451A3 (en) Insulin analog dimers
AR082422A1 (en) LIQUID DETERGENT COMPOSITION
CY1117300T1 (en) NEW ENHANCED PACKAGING WITH BUBBLES
CY1119036T1 (en) NEW AGGIOTENSIN (AT2) TYPE 2 RECEPTOR AGENTS AND THEIR USES
BR112013004294A2 (en) methods and materials for providing teeth with a white appearance.
ES2415029R1 (en) Pharmaceutical composition and method to inhibit the production or amplify the elimination of the P24 protein.
CY1113641T1 (en) PHARMACEUTICAL COMPOSITION INCLUDING ALEGLITAZAR
GR1007010B (en) INSULINOID Peptides